CEO’s 10‑b5‑1 Trading Plan Keeps United Therapeutics on a Predictable Path for Liquidity and Growth

Insider Activity Highlights a Strategic Trading Plan

On 13 October 2026, Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp., executed a 10 b5‑1 trading plan transaction that combined a buy of 9,500 shares at $117.76 with a series of sells totaling 6,390 shares at prices ranging from $542.76 to $550.59. The plan, which was adopted in November 2025, allows Rothblatt to sell options and convert them to shares under a pre‑arranged schedule, thereby reducing market timing risk. The net effect is a modest increase in her holdings, bringing her post‑transaction ownership to 333,943 shares.

Implications for Investors

The simultaneous buy and sell activity reflects a disciplined, plan‑driven approach rather than opportunistic trading. For investors, the key takeaway is that the CEO is not using insider information to capitalize on short‑term price swings; instead, she is fulfilling a long‑term liquidity plan. The transaction size—less than 0.2% of outstanding shares—minimises market impact, so it should not trigger volatility. However, the high number of shares sold in the same period could signal a desire to diversify risk or prepare for future option exercises, which may affect short‑term liquidity.

What the Activity Signals About the Company’s Future

United Therapeutics’ robust fundamentals—market cap of $23.6 billion, a 24.8% YTD gain, and a P/E of 19.6—suggest a healthy growth trajectory. The CEO’s structured plan indicates confidence in the company’s long‑term prospects while maintaining liquidity for potential future investments or personal needs. If the 10 b5‑1 plan continues, investors can expect periodic, predictable sales that provide an opportunity to benchmark the company’s share price against broader market movements without the risk of insider manipulation.

Rothblatt’s Transaction Pattern – A Profile

Rothblatt’s trading history over the last few weeks shows a consistent pattern of exercising options in a staggered fashion and selling the resulting shares in multiple trades. Since the 10 b5‑1 plan went into effect, she has executed roughly 60‑70 trades per month, selling shares at incremental price points from the low‑hundreds to the high‑five‑hundreds. Her buying activity remains limited to a few large purchases (e.g., 9,500 shares at $117.76), which are often paired with a subsequent sell of options‑derived shares. This disciplined cadence is typical of a “plan‑first, trade‑later” strategy used by top executives to mitigate conflict‑of‑interest concerns and align personal liquidity needs with corporate performance.

Key Takeaways for Market Participants

• Transparency: The 10 b5‑1 plan ensures that all trades are pre‑planned, reducing the perception of insider advantage.
• Liquidity Management: The CEO’s periodic sell‑down of option‑generated shares provides a cushion for future option exercises.
• Stable Ownership: Despite active trading, Rothblatt’s net ownership remains substantial, reinforcing confidence in United Therapeutics’ long‑term direction.

For analysts and investors, monitoring the continuation of this plan can serve as a gauge of management’s confidence and liquidity strategy, while the company’s solid biotech fundamentals and steady share performance provide a compelling backdrop for ongoing investment evaluation.